Secondary prevention of stroke in patients with atrial fibrillation: Factors influencing the prescription of oral anticoagulation at discharge

Cerebrovascular Diseases

Volumn 21, Issue 5-6, 2006, Pages 372-379

  Deplanque, Dominique ^a,g   Leys, Didier ^a   Parnetti, Lucilla ^b   Schmidt, Reinhold ^c   Ferro, Jose ^d   De Reuck, Jacques ^e   Mas, Jean Louis ^f   Gallai, Virgilio ^b  

^a UNIV LILLE   (France)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF GRAZ   (Austria)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f CENTRE HOSPITALIER SAINTE ANNE   (France)

^g Faculty of Medicine   (France)

Author keywords

Antiplatelet drugs; Atrial fibrillation; Oral anticoagulation; Secondary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HEPARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; AUSTRIA; BELGIUM; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; EUROPE; FEMALE; FRANCE; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; ITALY; LEUKOARAIOSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PORTUGAL; PRESCRIPTION; PRIORITY JOURNAL; BRAIN ISCHEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG UTILIZATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG UTILIZATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES;

EID: 33748453580     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091546     Document Type: Article

References (36)

1. European Atrial Fibrillation Trial Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
2. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-638.
3. Hart RG, Pearce LA, Koudstaal PJ: Transient ischemic attacks in patients with atrial fibrillation. Implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke 2004;35:948-951.
4. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ: Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:429S-456S.
5. Leys D, Kwiecinski H, Bogousslavsky J, Bath P, Brainin M, Diener HC, Kaste M, Sivenius J, Hennerici MG, Hacke W; EUSI Executive Committee; EUSI Writing Committee: Prevention. European Stroke Initiative. Cerebrovasc Dis 2004;17(suppl 2):15-29.
6. Evans A, Kalra L: Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 2001;161:1443-1447.
7. McCormick D, Gurwitz JH, Goldberg RJ, Becker R, Tate JP, Elwell A, Radford MJ: Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001;161:2458-2463.
8. Scott PA, Pancioli AM, Davis LA, Frederiksen SM, Eckman J: Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke 2002;33:2664-2669.
9. Go AS, Hylek EM, Borowsky LH, Philips KA, Selby JV, Singer DE: Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-934.
10. Deplanque D, Corea F, Arquizan C, Parnetti L, Mas JL, Gallai V, Leys D; SAFE I Study Investigators: Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? Heart 1999;82:563-569.
11. Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J, De Reuck J, Mas JL, Gallai V; SAFE II Investigators: Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004;57:798-806.
12. Albers GW, Bittar N, Young L, Hattemer CR, Gandhi AJ, Kemp SM, Hall EA, Morton DJ, Yim J, Vlasses PH: Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology 1997;48:1598-1604.
13. Brass LM, Krumholz HM, Scinto JD, Mathur D, Radford M: Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998;158:2093-2100.
14. Evans A, Perez I, Yu G, Kalra L: Secondary stroke prevention in atrial fibrillation. Lessons from clinical practice. Stroke 2000;32:2106-2111.
15. Evans A, Perez I, Yu G, Kalra L: Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke 2001;32:2828-2832.
16. Glader EL, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester PO, Asplund K; Riks-Stroke Collaboration: Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective. J Intern Med 2004;255:22-32.
17. Tentschert S, Parigger S, Dorda V, Bittner K, Unterbuchschachner D, Greisenegger S, Wimmer R, Brucke T, Lang W, Lalouschek W; Vienna Stroke Study Group: Recurrent vascular events in patients with ischemic stroke/TIA and atrial fibrillation in relation to secondary prevention at hospital discharge. Wien Klin Wochenschr 2004;116:834-838.
18. Mead GE, Lewis SC, Wardlaw JM, Dennis MS, Warlow CP: How well does the Oxfordshire community stroke project classification predict the site and size of the infarct on brain imaging? J Neurol Neurosurg Psychiatry 2000;68:558-562.
19. Mounier-Vehier F, Leys D, Rondepierre P, Godefroy O, Pruvo JP: Silent infarcts in patients with ischemic stroke are related to age and size of the left atrium. Stroke 1993;24:1347-1351.
20. Sulter G, Steen C, De Keyser J: Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538-1541.
21. Holstein MF, Folstein SE, McHugh PR: 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Bendel RB, Afifi AA: Comparison of stopping rules in forward regression. J Am Stat Assoc 1977;72:46-53.
23. Giroud M, Milan C, Beuriat P, Gras P, Essayagh E, Arveux P, Dumas R: Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischemic attacks: the stroke registry of Dijon, 1985-1989. Int J Epidemiol 1991;20:892-899.
24. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-428.
25. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE: Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141:745-752.
26. Connolly S; for the Atrial Fibrillation Investigators: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:1509.
27. The European Atrial Fibrillation Trial study Group: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral infarction. N Engl J Med 1995;333:5-10.
28. Penado S, Cano M, Acha O, Hernandez JL, Riancho JA: Atrial fibrillation as a risk factor for stroke recurrence. Am J Med 2003;114:206-210.
29. Gorter JW: Major bleeding during anticoagulation after cerebral ischemia. Patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999;53:1319-1327.
30. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM: Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002;59:193-197.
31. Lefebvre C, Deplanque D, Touzé E, Hénon H, Parnetti L, Pasquier F, Gallai V, Leys D; on behalf of the SAFE II investigators: Prestroke dementia in patients with atrial fibrillation: frequency and associated factors. J Neurol 2005;252:1504-1509.
32. The Atrial Fibrillation Investigators: The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. Arch Intern Med 1997;157:1237-1240.
33. EUROASPIRE I and II Group: Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
34. Landi F, Cesari M, Onder G, Zamboni V, Lattanzio F, Russo A, Barillaro C, Bernanei R; SILVERNET-HC Study Group: Antithrombotic drugs in secondary stroke prevention among a community dwelling older population. J Neurol Neurosurg Psychiatry 2003;74:1100-1104.
35. Monesi L, Avanzini F, Barlera S, Caimi V, Lauri D, Longoni P, Roccatagliata D, Tombesi M, Tognoni G, Roncaglioni MC: Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk? Eur J Clin Pharmacol 2005;61:595-601.
36. Poli D, Antonucci E, Lombardi A, Cecchi E, Corsini I, Gensini GF, Abbate R, Frisco D: Low incidence of hemorrhagic complications of oral anticoagulant therapy in patients with atrial fibrillation in the daily practice of an anticoagulation clinic. Ital Heart J 2003;4:44-47.